The deal intelligence
your committee expects.
14 engines. 12 therapeutic areas. 1,900+ transactions. Run rNPV, Monte Carlo, scenario modeling, and buyer-specific valuation — in under 30 seconds.
or $199/month billed annually
Total rNPV
$312M
+$87M option value
Cumulative PoS
24.3%
Ann. Return
18.4%
Payback
10.7y
rNPV
$312M
Implied Deal
$245M
Expected Value
$287M
Monte Carlo P50
$298M
Bear Floor
$85M
VaR (95%)
-$42M
CVaR (95%)
-$78M
Skewness
+0.84
Tail Risk
Moderate
See What Pro Unlocks
Every feature designed for deal committees, not dashboards.
Bear, Base, and Bull — side by side
Model three scenarios simultaneously with different PoS, peak sales, and discount rate assumptions. See the probability-weighted expected value across all outcomes.
- Scenario-specific rNPV with custom assumptions
- Compound scenarios — CRL + competitor launch, pricing squeeze + early generics
- Probability-weighted expected value across all outcomes
- Tornado chart: top 5 risks and top 5 upsides, ranked by dollar impact
Scenario Comparison
Bear
$85M
Deal: $28M
Base
$312M
Deal: $95M
Bull
$890M
Deal: $310M
Probability-Weighted Expected Value
$287M
Buyer-Specific Valuation
Generic Buyer
$245M
Upfront: $65M
AstraZeneca
$340M
+39% premium
Novartis
$295M
+20% premium
Negotiation Leverage
STRONGUpfront Premium
+$28MKnow what each buyer will pay — before the meeting
Compare Generic vs. up to 3 specific buyers side-by-side. The 5-factor strategic premium model accounts for portfolio fit, deal urgency, patent cliff pressure, pipeline gaps, and competitive pressure.
- 10-factor Pharma Intent Score per buyer
- Strategic premium capped at +75% (calibrated from 2,500+ deals)
- Negotiation leverage assessment
- Timing advantage analysis
850+ companies ranked by fit and acquisition intent
Our partner matching engine scores companies across modality alignment, pipeline gaps, patent cliff pressure, and deal velocity. The 10-factor Pharma Intent Score predicts who is most likely to transact in the next 12-18 months.
- Patent cliff revenue-at-risk analysis
- Pipeline gap detection from ClinicalTrials.gov
- Deal velocity and serial acquirer tracking
- Timing probability windows (6mo / 12mo / 18mo)
Top Partner Matches
14 Engines. One Platform.
Every engine runs in under 400ms. Results populate instantly.
Your Edge Between
Board Meetings
Two intelligence platforms that monitor 850+ companies and every deal that moves — so you walk into every meeting knowing what changed.
AstraZeneca plc
Large Pharma · Cambridge, UK · NASDAQ: AZN
Deals (3yr)
24
Intent Score
78
Acq. Appetite
High
Rev at Risk
$18B
Pipeline by Phase
Active Modalities
Know every buyer before
they know themselves
Deep profiles on 850+ biopharma companies updated weekly. Patent cliff pressure, pipeline gaps, acquisition appetite, and deal velocity -- the signals that predict who transacts next.
Deal financials and history
Every licensing, acquisition, and collaboration with disclosed terms
Patent cliff timelines
Revenue-at-risk analysis with LOE dates and biosimilar exposure
Pipeline gap detection
Active ClinicalTrials.gov monitoring across all phases and TAs
Acquisition appetite scoring
Composite signal from deal velocity, cash reserves, and pipeline depth
10-factor Pharma Intent Score
Predictive model calibrated against 378 historical transactions
Competitive peer mapping
Side-by-side comparison of pipeline overlap and strategic positioning
Intelligence that does not
sleep between Mondays
Weekly market snapshots with deal activity, benchmark shifts, and modality trends. Walk into every meeting knowing exactly what moved, what it means, and what comes next.
Live deal activity feed
Every announced transaction with terms, modality, phase, and TA classification
Benchmark trend analysis
12-month upfront and total deal value trends by modality and phase
Modality heatmaps
Visual grid showing where capital is concentrating across deal types
TA breakdown and shifts
Week-over-week changes in deal volume and value by therapeutic area
Historical sparklines
Inline trend visualization for every key metric and benchmark
Board-ready market context
Exportable insights formatted for deal committee presentations
Deals
23
+5 WoW
Announced
8
+2 WoW
Avg Upfront
$142M
+$18M WoW
Median
$85M
-$4M WoW
Latest Deals
Pfizer / Vanguard Biotech
ADC · Phase 2 · Oncology
Roche / NeuralPath
Bispecific Ab · Phase 1 · Neurology
Novartis / CellGenix
Cell Therapy · Phase 3 · Hematology
AbbVie / MetaboRx
Small Molecule · Phase 2 · Metabolic
Modality Heatmap (Deal Count)
ADC
mAb
SM
Gene
Cell
RNA
Bisp
PDC
mRNA
PROTAC
RNAi
Other
Free vs Pro
See exactly what you unlock.
Built for the People Making the Decisions
BD Teams
Active out-licensing
Model every scenario before you walk into the room. Compare partner offers side-by-side with buyer-specific assumptions.
Deal Committees
Evaluating inbound offers
Generate board-ready reports in minutes. rNPV, Monte Carlo, and sensitivity analysis give your committee quantitative rigor.
Investors & Advisors
Portfolio valuations
Stress-test deal economics across bear/base/bull. Real options valuation captures the optionality your DCF models miss.
Questions
Can I cancel anytime?
What's included in the annual plan?
Do I get access to all therapeutic areas?
Can I export reports for my deal committee?
Stop guessing. Start benchmarking.
1,900+ transactions. 14 engines. Under 30 seconds.
or $199/month annually
Cancel anytime. No contracts.